Bellicum appoints president, CEO
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Rick Fair was appointed Bellicum Pharmaceuticals Inc.'s president, CEO and member of the company's board.
Fair succeeds Tom Farrell who would serve as an adviser to the company during the transition. Fair was senior vice president and head of oncology global product strategy at Genentech, a Roche Holding Ltd. subsidiary.
